Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
about
Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression.Improved Tumor Penetration and Single-Cell Targeting of Antibody Drug Conjugates Increases Anticancer Efficacy and Host Survival.Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.Current status and future challenges for molecular imaging.First-in-human HER2-targeted imaging using 89Zr-pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer.Targeting HER2 in Nuclear Medicine for Imaging and Therapy.Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer.Cancer: Imaging with antibodies.Aligning physics and physiology: Engineering antibodies for radionuclide delivery.I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma.Long-Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer.Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness study.Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo.Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast CancerDedicated Breast Gamma Camera Imaging and Breast PET: Current Status and Future DirectionsUltrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancerNoninvasive assessment of characteristics of novel anti-HER2 antibodies by molecular imaging in a human gastric cancer xenograft-bearing mouse model
P2860
Q33841547-11BFE937-C925-4B4E-87C3-A64E9B99D26DQ37621295-31093ABD-A03E-4F09-8C23-096DFB9306FEQ39233197-7D57779E-7624-4A14-9F93-48FC94B0527BQ39346715-ADBCE57A-46C3-4558-8502-20874960D49DQ40208474-78804D96-B36C-44CF-A142-6500BA45CDD5Q40409656-C8909CB8-01A4-4EDC-B76C-3B393357B417Q47158578-7C5FA3EE-C4A0-46B7-8AF6-EC1DEFB0D53BQ47271330-5A57D3F7-5C67-42D6-A996-56A6E73E3156Q47573583-0B21E4A6-B618-4C6C-83A3-A079F2CE884CQ47646469-74C3D96A-A67C-4B07-AD4F-B545CA4FB325Q47965803-E12616B0-6315-411E-9C4E-F1946D831DE0Q49700421-48BE9AD4-81EF-4B2D-9199-1BED77E496FEQ50016491-6AE46134-6F12-4381-8713-A2A363ACE5ACQ50223041-B52E7105-4EB2-42AD-91D0-A0BE445216F4Q50571860-EB7CFB22-8488-455D-BDC8-6F5050368FFAQ51081078-81F82DE8-F5B8-4F43-912F-283DE87A0EC0Q51740406-E6E329F5-88B0-469B-81BF-B0F225AA53B1Q52672750-984E7C87-7E1B-4787-9A11-3DA4B724F1B9Q53106375-82B0C542-B47A-449E-9980-A73A1A214801Q55040337-8E801039-5386-43C8-B3A8-2EAAED931FF4Q55286461-A80F0708-8AC3-48EE-B3D9-44CDD182C93BQ57110662-E4394E1A-0DA2-4339-8483-736A414F5782Q57178839-3F145A57-879E-4540-838F-A2F619B2EC9FQ57295430-019092F3-DBAA-4E60-8D5E-114502E6DFCAQ58743797-3C97BBBD-FA12-4438-8328-9833BF377BF6
P2860
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Detection of HER2-Positive Met ...... Using 89Zr-Trastuzumab PET/CT
@en
Detection of HER2-Positive Met ...... Using 89Zr-Trastuzumab PET/CT.
@nl
type
label
Detection of HER2-Positive Met ...... Using 89Zr-Trastuzumab PET/CT
@en
Detection of HER2-Positive Met ...... Using 89Zr-Trastuzumab PET/CT.
@nl
prefLabel
Detection of HER2-Positive Met ...... Using 89Zr-Trastuzumab PET/CT
@en
Detection of HER2-Positive Met ...... Using 89Zr-Trastuzumab PET/CT.
@nl
P2093
P2860
P50
P1476
Detection of HER2-Positive Met ...... Using 89Zr-Trastuzumab PET/CT
@en
P2093
Adriana Corben
Dara S Ross
David M Hyman
Hartmuth Kolb
Heather McArthur
Joseph P Erinjeri
Sarat Chandarlapaty
Serge K Lyashchenko
Shari Goldfarb
Stephen B Solomon
P2860
P304
P356
10.2967/JNUMED.115.172031
P407
P577
2016-05-05T00:00:00Z